Lindy N M Gommans1, Hugo J P Fokkenrood2, Hendrika C W van Dalen1, Marc R M Scheltinga3, Joep A W Teijink4, Ron J G Peters5. 1. Department of Vascular Surgery, Catharina Hospital, Eindhoven, The Netherlands. 2. Department of Vascular Surgery, Catharina Hospital, Eindhoven, The Netherlands; Care and Public Health Research Innovation (CAPHRI) Research School, Maastricht University, Maastricht, The Netherlands. 3. Cardiovascular Research Institute Maastricht (CARIM) Research School, Maastricht University, Maastricht, The Netherlands; Department of Vascular Surgery, Maxima Medical Centre, Veldhoven, The Netherlands. 4. Department of Vascular Surgery, Catharina Hospital, Eindhoven, The Netherlands; Care and Public Health Research Innovation (CAPHRI) Research School, Maastricht University, Maastricht, The Netherlands. Electronic address: joep.teijink@catharinaziekenhuis.nl. 5. Department of Cardiology, Academic Medical Centre, Amsterdam, The Netherlands.
Abstract
BACKGROUND: Supervised exercise therapy (SET) is recommended as the primary treatment for patients with intermittent claudication (IC). However, there is concern regarding the safety of performing SET because IC patients are at risk for untoward cardiovascular events. The Dutch physical therapy guideline advocates cardiac exercise testing before SET, if indicated. Perceived uncertainties concerning safety may contribute to the underuse of SET in daily practice. The objective of this review was to analyze the safety of supervised exercise training in patients with IC. METHODS: Two authors independently studied clinical trials investigating SET. Data were obtained from MEDLINE, EMBASE, and The Cochrane Central Register of Controlled Trials. Complication rates were calculated and expressed as number of events per number of patient-hours. The usefulness of cardiac screening before SET was evaluated in a subanalysis. RESULTS: Our search strategy revealed 2703 abstracts. We selected 121 articles, of which 74 met the inclusion criteria. Studies represent 82,725 hours of training in 2876 IC patients. Eight adverse events were reported, six of cardiac and two of noncardiac origin, resulting in an all-cause complication rate of one event per 10,340 patient-hours. CONCLUSIONS: SET can safely be prescribed in patients with IC because an exceedingly low all-cause complication rate was found. Routine cardiac screening before commencing SET is not required. Our results may diminish perceived uncertainties regarding safety and will possibly increase the use of SET in daily practice.
BACKGROUND: Supervised exercise therapy (SET) is recommended as the primary treatment for patients with intermittent claudication (IC). However, there is concern regarding the safety of performing SET because IC patients are at risk for untoward cardiovascular events. The Dutch physical therapy guideline advocates cardiac exercise testing before SET, if indicated. Perceived uncertainties concerning safety may contribute to the underuse of SET in daily practice. The objective of this review was to analyze the safety of supervised exercise training in patients with IC. METHODS: Two authors independently studied clinical trials investigating SET. Data were obtained from MEDLINE, EMBASE, and The Cochrane Central Register of Controlled Trials. Complication rates were calculated and expressed as number of events per number of patient-hours. The usefulness of cardiac screening before SET was evaluated in a subanalysis. RESULTS: Our search strategy revealed 2703 abstracts. We selected 121 articles, of which 74 met the inclusion criteria. Studies represent 82,725 hours of training in 2876 IC patients. Eight adverse events were reported, six of cardiac and two of noncardiac origin, resulting in an all-cause complication rate of one event per 10,340 patient-hours. CONCLUSIONS: SET can safely be prescribed in patients with IC because an exceedingly low all-cause complication rate was found. Routine cardiac screening before commencing SET is not required. Our results may diminish perceived uncertainties regarding safety and will possibly increase the use of SET in daily practice.
Authors: Marie D Gerhard-Herman; Heather L Gornik; Coletta Barrett; Neal R Barshes; Matthew A Corriere; Douglas E Drachman; Lee A Fleisher; Francis Gerry R Fowkes; Naomi M Hamburg; Scott Kinlay; Robert Lookstein; Sanjay Misra; Leila Mureebe; Jeffrey W Olin; Rajan A G Patel; Judith G Regensteiner; Andres Schanzer; Mehdi H Shishehbor; Kerry J Stewart; Diane Treat-Jacobson; M Eileen Walsh Journal: Circulation Date: 2016-11-13 Impact factor: 29.690
Authors: David Hageman; Hugo Jp Fokkenrood; Lindy Nm Gommans; Marijn Ml van den Houten; Joep Aw Teijink Journal: Cochrane Database Syst Rev Date: 2018-04-06
Authors: Marie D Gerhard-Herman; Heather L Gornik; Coletta Barrett; Neal R Barshes; Matthew A Corriere; Douglas E Drachman; Lee A Fleisher; Francis Gerry R Fowkes; Naomi M Hamburg; Scott Kinlay; Robert Lookstein; Sanjay Misra; Leila Mureebe; Jeffrey W Olin; Rajan A G Patel; Judith G Regensteiner; Andres Schanzer; Mehdi H Shishehbor; Kerry J Stewart; Diane Treat-Jacobson; M Eileen Walsh Journal: Circulation Date: 2016-11-13 Impact factor: 29.690
Authors: Bogdan Pietraszewski; Marek Woźniewski; Ryszard Jasiński; Artur Struzik; Andrzej Szuba Journal: Biomed Res Int Date: 2019-05-27 Impact factor: 3.411
Authors: Elke Bouwens; Sanne Klaphake; Karin J Weststrate; Joep Aw Teijink; Hence Jm Verhagen; Sanne E Hoeks; Ellen V Rouwet Journal: Vasc Med Date: 2019-02-22 Impact factor: 3.239
Authors: Marijn Ml van den Houten; Sandra Cp Jansen; Anneroos Sinnige; Lijckle van der Laan; Patrick Whe Vriens; Edith M Willigendael; Jan-Willem Hp Lardenoije; Jan-Willem M Elshof; Eline S van Hattum; Maarten A Lijkwan; Ivan Nyklíček; Ellen V Rouwet; Mark Jw Koelemay; Marc Rm Scheltinga; Joep Aw Teijink Journal: BMJ Open Date: 2019-02-19 Impact factor: 2.692
Authors: Amy E Harwood; Sean Pymer; Lee Ingle; Patrick Doherty; Ian C Chetter; Belinda Parmenter; Christopher D Askew; Gary A Tew Journal: BMJ Open Sport Exerc Med Date: 2020-11-05